Medicortex Finland Oy Announces Issuance of a Patent in the United States

“This is our biggest achievement by now, we are extremely pleased with the development of the patent portfolio” said Dr. Harel Adrian, Chief Executive Officer of Medicortex. “This new issuance continues to expand the intellectual property portfolio covering methods of using certain biomarkers for detection of concussion. The issuance of this patent is another step in the development of a robust patent portfolio relating to new strategy to help identify and treat mild TBI” Dr. Harel continued with great pleasure.

Medicortex is currently developing a rapid diagnostic kit for detection of concussion and mild traumatic brain injury from urine or saliva. The kit is based on specific biomarkers that the company has discovered from body fluids following brain injury. Such a rapid kit will satisfy the urgent need to improve the detection of brain injury in mild cases especially – which are known to be potentially morbid but difficult to diagnose with the contemporary means. The issued patent covers the core technology and method for detecting novel glycan-based biomarkers which are indicative of traumatic brain injury.

The issued US patent No. 10,739,335 “Prognostic and Diagnostic Glycan-Based Biomarkers of Brain Damage” is the second grant in the patent family where relative national patents were previously issued by the European Patent Office (EPO). Patenting of disease biomarkers and related diagnostics is becoming very tough in the USA, so the allowance of the current patent is a great achievement in that sense.

Medicortex’ patent portfolio encompasses diagnostics of TBI biomarkers as well as relative drug candidates developed by the company. The comprehensive patent coverage secures exclusivity to develop the products and the company’s strategy is to actively seek new patentable innovations from its biomarker and drug development programs.